NCT04125888 is a clinical trial of Allergy immunotherapy (AIT) in Allergy, sponsored by ALK-Abelló A/S.

Who is sponsoring NCT04125888?

NCT04125888 is sponsored by ALK-Abelló A/S.

What drugs are being tested in NCT04125888?

Interventions in NCT04125888: Allergy immunotherapy (AIT).

What condition does NCT04125888 study?

NCT04125888 studies Allergy, Respiratory Disease.

Is NCT04125888 still recruiting?

NCT04125888 is currently completed. Last updated 2 June 2021.

Last reviewed 2021-06-02 · How we verify

NCT04125888

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of AIT on Allergic Rhinitis and Asthma

Completed Last updated 2 June 2021

What this trial tests

trial testing Allergy immunotherapy (AIT) in Allergy in 92,048 participants. Completed in 16 April 2021.

Timeline

22 July 2019

Primary endpoint
16 April 2021

16 April 2021

Quick facts

Lead sponsor	ALK-Abelló A/S
Status	Completed
Study type	OBSERVATIONAL
Enrollment	92,048
Start date	22 July 2019
Primary completion	16 April 2021
Estimated completion	16 April 2021
Sites	1 location across Denmark

Drugs / interventions tested

Allergy immunotherapy (AIT) — full drug profile →

Conditions studied

Allergy — all drugs for Allergy →
Respiratory Disease — all drugs for Respiratory Disease →

Sponsor

ALK-Abelló A/S — full company profile →

Who can join

Eligibility, any sex, with Allergy or Respiratory Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will assess the effectiveness of AIT treatment in real clinical practice in Germany.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study.
Fritzsching B, Contoli M, Porsbjerg C, Buchs S, et al · · 2022 · cited 83× · PMID 34901915 · DOI 10.1016/j.lanepe.2021.100275
High baseline prevalence of atopic comorbidities and medication use in children treated with allergy immunotherapy in the REAl-world effeCtiveness in allergy immunoTherapy (REACT) study.
Fritszching B, Porsbjerg C, Buchs S, Larsen JR, et al · · 2023 · cited 5× · PMID 37063677 · DOI 10.3389/fped.2023.1136942
Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma.
Woehlk C, Stranzl T, Contoli M, Freemantle N, et al · · 2025 · cited 1× · PMID 41031547 · DOI 10.1111/all.70085

Verify or expand the search:

Other recruiting trials for Allergy

Currently open trials in the same condition.

NCT05997784 — Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing · active not recruiting
NCT06390878 — Nationwide Research on the Rewilding of Kindergarten Yards · NA · recruiting
NCT06248957 — SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION · recruiting
NCT05449756 — A Follow-up Study With Children Who Participated in the TEMPO Study in Their First Year of Life · recruiting
NCT06192914 — EPAP, Interviewstudy · recruiting

Other ALK-Abelló A/S trials

Trials by the same sponsor.

NCT06151938 — Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis · unknown
NCT05881577 — The Effect of Allergic Rhinitis on Educational Outcomes · unknown
NCT05655858 — Observational Study of Allergic Rhinitis in Children · completed
NCT04881461 — A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis · Phase 3 · completed
NCT04878354 — A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04125888 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ALK-Abelló A/S
Last refreshed: 2 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04125888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing